Ke Wu

Ke Wu

Auto-generated profile, based on publicly available information

Ke Wu

School of Clinical Medicine, Guizhou Medical University Guiyang China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
PDF file
KWKe Wu
Ke Wu
JWJing Wang
Jing Wang
LZLimin Zhao
Limin Zhao
PWPei Wang
Pei Wang
QDQi Duan
Qi Duan
Objective: To investigate the effect of non‐small cell lung cancer (NSCLC) combined with Chronic Obstructive Pulmonary Disease (COPD) on prognosis, so as to provide help to clinical diagnosis and treatment.Methods: PubMed, Web of Science and the Medline were used to retrieve studies reported from 1950 to 2019. If the study reported the prognosis of COPD with NSCLC, the study was included and the relevant information was extracted and the data analyzed. The standard mean deviation (SMD) of 95% confidence interval was used in this meta‐analysis.Results: A total of 851 data studies were reviewed for eligibility, eventually, 12 case‐control studies were included in this systematic review and meta‐analysis. The sample sizes for company's studies of NSCLC ranged from 85 to 10 378, with a total number of 14 164, including 2450 COPD and 9395 Non‐COPD. Meta‐analyses showed that concomitant COPD was associated with poorer OS compared with patients without COPD (Fixed: HR: 1.16; 95% CI: 1.08‐1.25. Random: HR: 1.07; CI: 0.92‐1.24), with a significant heterogeneity across studies (I2 = 45%, P = 0.04).Conclusion: Our study showed that patients with combined COPD had an impact on the prognosis and survival rate of SCLC patients.

12 December 2022 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
JWJing Wang
Jing Wang
KWKe Wu
Ke Wu
XCXianliang Cheng
Xianliang Cheng
XCXiangsong Chen
Xiangsong Chen
YQYanan Qi
Yanan Qi
LZLimin Zhao
Limin Zhao
Background: Exhaled nitric oxide (FeNO) is a simple, noninvasive, and reproducible test, and FeNO (50 ml/s) is often used to reflect airway inflammation. The peripheral small airway/alveolar nitric oxide (NO) concentration is derived from the output of NO at multiple flow rates. Concentration of alveolar NO (CANO), which has been reported to reflect peripheral small airway inflammation, may be related to parameters that reflect abnormal small airway function.Aim: This study aims to investigate the relationship among CANO levels, clinical features, and small airway function‐related indicators in patients with stable asthma and to provide a simple method for monitoring small airway function in asthma.Design and Methods: We recruited 144 patients with well‐controlled, stable asthma, including 69 patients with normal small airway function (normal group) and 75 patients with small airway dysfunction (abnormal group). CANO and pulmonary function were measured.Results: CANO was significantly higher in the abnormal group ([7.28 ± 3.25] ppb) than the normal group CANO ([2.87 ± 1.50] ppb). FEF25–75%pred ([55.0 ± 16.5]%), FEF50%pred ([46.4 ± 13.2]%), and FEF75%pred ([41.9 ± 13.1]%) in abnormal group were significantly lower compared with normal group ([89.9 ± 7.5]%), ([80.9 ± 6.8]%), and ([73.8 ± 5.0]%). CANO was negatively correlated and FEF25–75%pred, FEF50%pred, and FEF75%pred (r = −0.87, P < 0.001; r = −0.82, P < 0.001; r = −0.78, P < 0.001). CANO was positively correlated with age (r = 0.27, P = 0.001). The area under the ROC curve was 0.875 for CANO. The optimal cutoff point of 5.3 ppb had sensitivity and specificity values of 72% and 92% in diagnosing small airway dysfunction.Conclusion: CANO has diagnostic value for small airway dysfunction, and the optimal cutoff value is 5.3 ppb. However, the diagnostic evidence is still insufficient, so it still needs further exploration for its value in detecting small airway dysfunction.